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Abstract
Lung cancer is the leading cause of cancer deaths. Unfortunately, lung cancer is often
diagnosed only when it becomes symptomatic or at an advanced stage when few treatment
options are available. Hence, a diagnostic test suitable for screening widespread populations is
required to enable earlier diagnosis. Analysis of exhaled breath provides a non-invasive
method for early detection of lung cancer. Analysis of volatile organic compounds (VOCs) by
various mass spectral techniques has identified potential biomarkers of disease. Nevertheless,
the metabolic origins and the disease specificity of VOCs need further elucidation. Cell culture
metabolomics can be used as a bottom-up approach to identify biomarkers of pathological
conditions and can also be used to study the metabolic pathways that produce such
compounds. This paper summarizes the current knowledge of lung cancer biomarkers in
exhaled breath and emphasizes the critical role of cell culture conditions in determining the
VOCs produced in vitro. Hypoxic culture conditions more closely mimic the conditions of
cancer cell growth in vivo. We propose that since hypoxia influences cell metabolism and so
potentially the VOCs that the cancer cells produce, the cell culture metabolomics projects
should consider culturing cancer cells in hypoxic conditions.
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Introduction
Lung cancer is one of the five most commonly diagnosed
cancers and is the leading cause of cancer-related deaths
throughout the world [1–3]. The 5 year survival rate for lung
cancer patients is poor, largely due to symptoms of lung cancer
usually becoming apparent only once the disease has reached
an advanced stage. Methods for the detection of lung cancer
are generally invasive and not suited to widespread population
screening; hence, there is a need for a non-invasive, accurate
and rapid screening test for early detection.
Content from this work may be used under the terms of
the Creative Commons Attribution 3.0 licence. Any further
distribution of this work must maintain attribution to the author(s) and the
title of the work, journal citation and DOI.
The exhaled breath of lung cancer patients contains
volatile organic compounds (VOCs), some of which may
be useful biomarkers of the disease and, therefore, provide
a non-invasive means to screen for lung cancer using
gas chromatography-mass spectrometry (GC-MS). Previous
results indicate that lung cancer can be diagnosed in this way
with some accuracy [4]. The diagnostic VOCs identified in
these studies were mostly alkanes that showed decrease in
exhaled breath compared to room air, which is believed to
occur due to metabolism by cytochrome P450 mixed function
oxidases that are up-regulated in cancer. However, most lung
cancer VOCs that have been reported are not disease specific
and their metabolic origins remain unknown. Knowledge of
all the VOCs produced by lung cancer cells should lead to a
panel of diagnostic biochemical markers that can be measured
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Table 1. Volatile compounds associated with disease [11].
Volatile compound(s) Disorder(s)
Ethane and pentane Oxidative stress
Methylated hydrocarbons Lung or breast cancer
Isoprene Cholesterol metabolism
Acetone Diabetes mellitus,
ketonemia
Dimethylsulfide, methyl Liver damage
mercaptane, ethyl mercaptane
Ammonia, dimethylamine, Uremia, renal damage
trimethylamine
in combination to increase the sensitivity and specificity of
lung cancer diagnosis.
The use of cell culture metabolomics allows for both
the discovery of novel biomarkers of pathological conditions
and investigation of the metabolic pathways that produce
them. However, previous studies have found poor correlations
between the VOCs from cancer cells in culture and those found
by breath analysis (see section 2 of this paper). We propose
that one reason for this discrepancy is the use of hyperoxic in
vitro culture conditions that have traditionally been used for
growing cancer cell lines. In vivo cancer cells experience low
oxygen or hypoxic conditions as a consequence of the diffusion
limit within tissues, which has been measured to be around
150 μm [5, 6]. Consequently, once a tumour grows to greater
than 300 μm diameter or approximately 15 to 20 cells across,
the cells in the centre will be experiencing hypoxic conditions.
VOCs however are generally hydrophobic and therefore lipid
soluble and so should pass freely from the hypoxic regions of
the tumour to enter the circulation to travel to the lungs for
release by breath.
There have been several excellent recent reviews of the
VOCs associated with lung cancer [7, 8]. In this paper, we
summarize the current state of knowledge about biomarkers
of lung cancer in exhaled breath but with an emphasis
on the critical role of cell culture conditions in in vitro
studies in determining the VOCs produced. Hypoxic culture
conditions more closely mimic the conditions of cancer cell
growth in vivo. Since hypoxia influences cell metabolism,
then it will also influence the VOCs produced by the cancer
cells. Consequently, cell culture metabolomics projects should
consider culturing cancer cells in hypoxic conditions.
1. Breath analysis
1.1. Pros and cons of breath analysis
Breath analysis provides a non-invasive window to observe
the biochemical processes of the body [9]. Ancient physicians
knew that the smell of human breath can indicate a certain
disease state which could be a useful diagnostic tool. For
example, diabetes is associated with the sweet smell of acetone
in breath, renal failure results in a urine-like smell and fishy
odour in breath is linked to liver disease [10] (table 1).
VOCs are only a small fraction of the total chemical
compounds present in human breath and occur at low
concentrations in the nmol l−1–pmol l−1 range [9, 12].
Table 2. VOCs—biological origin.
VOCs Biological basis
Acetaldehyde Ethanol metabolism [29, 30]
Acetone Decarboxylation of acetoacetate
and acetyl-CoA
Ethane and pentane Lipid peroxidation [9]
Ethylene Lipid peroxidation [31]
Hydrogen and methane Gut bacteria [32]
Isoprene Cholesterol biosynthesis [33]
Methylamine Protein metabolism [31]
The origin of these volatile substances may be endogenous
(generated within the body) or exogenous (absorbed as
contaminants from the environment). Targeting the volatile
component of breath for analysis reduces many issues
associated with analysis of total breath. Currently, clinically
available breath tests include: breath-alcohol test which
determines ethanol concentration [13], the nitric oxide (NO)
test to detect asthma and diagnosis of Helicobacter pylori
infection by 13C-urea or ammonia breath tests [14].
In 1971, Pauling et al detected the presence of
large numbers of VOCs using microanalysis of breath by
newly developed capillary gas chromatography (GC) [15].
Apparently, there are approximately 200 VOCs present in
the exhaled breath in picomolar concentrations [16] and there
have been studies which aim to correlate single substances or
sets of exhaled markers and the clinical conditions of patients
[17–21]. Analysis of exhaled breath has many advantages
compared to other diagnostic techniques such as bronchoscopy
or medical imaging. It is non-invasive and painless and exhaled
air can be sampled as often as necessary without restriction;
particularly important for the critically ill and for large scale
screening in healthy populations for cancer, renal and liver
diseases. The basic research in breath analysis relies on
the advances of analytical technology to detect and identify
the VOCs. The sample of exhaled breath is analysed using
various high-performance equipment such as GC-MS, selected
ion-flow tube mass spectrometry (SIFT-MS), ion-mobility
spectrometry (IMS) and proton transfer mass spectrometry
(PTR-MS).
These methods of diagnosis are potentially useful in
clinical practice but they are not yet available as portable
analytical devices. Also, standardization of protocols for
collection and analysis of exhaled breath must occur in order
to achieve consistency in VOC profile analysis [22, 23].
1.2. Biological mechanisms
The origins of many VOCs have now been explained through
an improved understanding of the mechanisms and kinetics of
VOC synthesis [4] (and for a review see [7]) (table 2). Alkanes
and methylated alkanes in breath are markers of oxidative
stress, which are the products of reaction of lipids with reactive
oxygen species (ROS). ROS comprise oxygen free radicals
and hydrogen peroxide and are constantly produced in the
mitochondria from where they can leak into the cytoplasm
[24]. Cellular anti-oxidant defences such as glutathione (in
reduced form) usually protect cells from ROS, but when these
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defences are insufficient ROS causes peroxidative damage to
proteins, polyunsaturated fatty acids and DNA [25]. These
peroxidative changes to DNA bases may be carcinogenic
[26, 27]. Considerable evidence supports the hypothesis that
oxidative stress appears to be increased in some cancers [28]
including lung cancer [16].
Breath methyl alkanes may be products of lipid
peroxidation of polyunsaturated fatty acids in cell membranes,
a process that also generates alkanes such as ethane and
pentane that are found in exhaled breath [34]. Alkanes
are metabolized to alkyl alcohols by cytochrome P450
(CYP)—mixed function oxidase enzymes [35] and a number
of studies have demonstrated that these enzymes are
activated in lung cancer [36–39]. For example, polyaromatic
hydrocarbons in tobacco smoke induce CYP 1A1 and CYP
1A2 activity, resulting in the accelerated drug metabolism
and activation of some procarcinogens [40]. Consequently,
the biotransformation of volatile alkanes and monomethylated
alkanes that are produced by oxidative stress may be
accelerated by CYP enzymes that have been activated in
patients with lung cancer so producing aldehydes, alcohols
and ketones in measurable quantities in breath [4].
1.3. VOCs identified in breath of cancer patients
A number of studies have detected chemical compounds in
breath samples from patients with and without lung cancer
[15, 16, 39–42]. Although the VOCs identified as markers
of lung cancer differ between reports, the results have all
shown significant variations between exhaled breath of lung
cancer patients and healthy volunteers [41]. The source and
physiological function of most lung cancer VOCs, however,
are still unknown [42]. Some of them could be of exogenous
origin and so be inhaled, absorbed from the lungs and
metabolized in the body, and the metabolites excreted by
expiration. Other VOCs that are of endogenous origin may
be generated as products of internal metabolic processes or
activity of intestinal bacteria [41].
VOCs found in the breath of lung cancer patients
include a wide range of aldehydes, alkanes and methylated
alkanes containing C2–C11 carbons. Some studies have
reported alkenes and aromatic compounds such as
benzene, ethyl benzene, xylene isomers, acetonitrile, 2-
methyl furan, 2,5-dimethyl furan, furan, 1,3-cyclohexadiene,
1,3-cyclopentadiene, 2-methyl-1-butene and 1,4-pentadiene,
which are all related to cigarette smoking [43, 44].
As analytical technology rapidly advances, so has the
detection of compounds in breath. Many compounds have
been detected whose biochemical origin is unknown and many
VOC metabolites reported as biomarkers have been found not
to be disease specific. Hence, validation of the biomarkers is a
necessary step in developing a specific and sensitive test for the
early detection of lung cancer. In vitro analysis of established
cancer cell lines is an approach that should help identify
endogenous VOCs and define the underlying mechanisms that
lead to quantitative or qualitative changes in lung cancer.
2. Cell culture metabolomics
2.1. Validation of biomarkers
Metabolomics, a high-throughput global metabolite analysis,
is a burgeoning field with an emerging role in cancer diagnosis,
recurrence and prognosis through identifying novel cancer
biomarkers [45].
The integrated analysis of metabolomics and other
‘omics’ technologies may provide more sensitive ways
to detect changes related to disease and discover novel
biomarkers [46]. Subtle changes in metabolism can be detected
by analyses of the products of cellular processes which in turn
can lead to the development of prognostic models useful for
early detection of cancer.
The metabolome is downstream of the transcriptome and
proteome, and is considered to be complementary to genomics,
transcriptomics and proteomics [47, 48]. Understanding the
metabolome may also assist in identifying intermediate or
surrogate cancer biomarkers for establishing preventive or
therapeutic approaches for health [46].
VOCs in breath can derive from cancer cells, healthy
cells, immune cells and microbes [49]. Several studies have
investigated the release of VOCs from human cancer cells
in vitro [49–53], for example, headspace on-line measurements
by SIFT-MS were able to detect acetaldehyde release from the
lung cancer cell lines SK-MES and CALU-1 [52].
If some breath markers of lung cancer do derive from
the cancer cells themselves, then there should be an overlap
between the set of VOCs produced by cancer cells in culture
and the VOCs detected in the breath of lung cancer patients.
Comparison of the VOC profiles of breath analysis and cell
cultures (table 3) reveals that, of the 68 VOCs detected in
either breath or cell culture, only 16 VOCs were detected in
both cell culture and breath. There were an additional 17 VOCs
detected only in breath and 22 found only in lung cancer cell
cultures and 13 VOCs found only in controls (non-transformed
cell lines). This poor relationship indicates that in vitro culture
of lung cancer cells is not a good model for the production
of VOCs in breath of lung cancer patients. A more detailed
examination of the compounds identified shows that of the 16
compounds common to both cell culture headspace and lung
cancer breath, five were straight chain alkanes and methylated
alkanes, which is consistent with lipid breakdown associated
with oxidative stress [13, 41]. Interaction of active oxygen
species with polyunsaturated fatty acids such as linoleic acid
and palmitic acid in the cell membrane results in a series
of reactions called lipid peroxidation. During the process of
peroxidation of polyunsaturated fatty acids volatile alkanes are
formed that can be excreted in breath unchanged or distributed
throughout the body, partly metabolized and then excreted in
breath.
The remainder of the compounds common to breath and
cell culture were alkenes, aldehydes and aromatic compounds,
some of which are also associated with lipid peroxidation
[9, 30]. Of the 22 compounds found only in cell culture
most were alcohols, ketones, esters and ethers (table 3)
suggesting that the VOCs produced by cancer cell culture
are mostly oxidized breakdown products. Other analytical
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Table 3. Comparison of VOCs found in breath and in vitro analysis of cells cultured under standard hyperoxic conditions.
In vitro In vitro
Class Compound Structure Breath (normal cells) (cancer cells) References
Hydrocarbons
Alkanes Pentane +a − − [54]
(straight chain)
Heptane + − − [54]
Octane +
b(hFB) (A549)
[51, 54]
Decane + − [16, 50, 54–56]
Undecane + − [16, 43, 53]
Alkanes 2-methyl pentane + − − [49, 54]
(branched)
2,3,3-trimethylpentane −
(hFB&HBEpC) (NCI−H2087)
[51, 53]
2,3,4-trimethyl pentane − − [51]
2,4-dimethyl hexane − − [51]
2,3,5-trimethyl hexane 1
(Calu−1)
[51, 53]
2-methyl heptane + − − [16]
3-methyl heptane − − [51]
4-methyl heptane − − [51]
2,4-dimethyl heptane + −
(Calu−1)
[16, 53]
2,2,4,6,6-pentamethyl + − − [54]
heptane
3-methyl octane + − − [16]
4-methyl octane + −
(Calu−1)
[53]
3-methyl nonane + − − [16]
Cycloalkanes 1-methyl-2-pentyl + − − [16]
cyclopropane
Methyl cyclo pentane + − + [16, 50]
Cyclo hexane + [16]
Alkenes 1-hexene + − + [16, 50]
1-heptene + − − [16]
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Table 3. (Continued).
In vitro In vitro
Class Compound Structure Breath (normal cells) (cancer cells) References
2,4,dimethyl-1-heptene −
(A549)
[51]
2-methyl -1,3-butadiene + − + [16, 50, 54]
(Isoprene)
Alcohols Ethanol − −
(A549)
[51]
2-methyl-1-propanol −
(hFB)
− [51]
2-methyl-2-propanol −
(HBEpC)
− [51]
3-methyl-1-butanol −
(hFB)
− [51]
2-ethyl-1-hexanol −
(hFB) (NCI−H2087)
[49]
Aldehydes formaldehyde + − − [57]
Acetaldehyde +
(NCI−H2087,
[49, 52, 53]
CALU-1)
2-methyl propanal −
(A549,NCI−H2087,
[49, 51, 53]
Calu-1)
Butanal − −
(A549)
[51]
Pentanal + − − [58]
Hexanal +
(NCI−H1666,Calu−1)
[16, 50, 58–60]
Heptanal + − + [16,50,58–60]
Octanal + − [58]
Nonanal + − − [58]
prop-2-enal − −
(Calu−1)
[53]
2-methylprop-2-enal −
(HBEpC) (A549,NCI−H1666,
[51, 53, 59]
Calu-1)
2-ethylprop-2-enal − −
(A549,Calu−1)
[51, 53]
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Table 3. (Continued).
In vitro In vitro
Class Compound Structure Breath (normal cells) (cancer cells) References
2-butenal − − [51]
2-methyl-2-butenal − −
(A549,Calu−1)
[51, 53]
2-methyl butenal −
(NCI−H2087)
[49, 51]
3-methyl butenal − [49, 51, 53, 59]
Benzaldehyde −
(Calu−1)
[51, 53]
Ketones Acetone −
(A549)
[51]
2-butanone − −
(Calu−1)
[53]
2-pentanone − [51]
2-hexanone − − [51]
3-pentene-2-one − − [51]
1-phenyl ethanone + − − [16]
Esters Methyl acetate − − [51]
n-propyl acetate − − [51]
n-butyl acetate − − [51]
Ethers Methyl-tert-butyl −
(HBEpC) (A549)
[51], [53]
ether
(Calu−1)
Ethyl-tert-butyl −
(hFB) (A549)
[51], [53]
ether
(Calu−1)
Aromatics Benzene +
(hFB)
+ [16,50, 51, 54–56, 61]
Toluene + − − [54]
Styrene + − + [16, 50, 51, 54–56, 61]
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Table 3. (Continued).
In vitro In vitro
Class Compound Structure Breath (normal cells) (cancer cells) References
Ethyl benzene + − − [55]
Propyl benzene + − + [50, 54, 56]
Trimethyl benzene isomers + − + [16, 50, 54]
Xylene isomers + − − [16, 62]
Heterocyclics Tetrahydro Furan − −
(Calu−1)
[53]
pyrrole − −
(A549)
[51]
Nitriles Acetonitrile − −
(Calu−1)
[53]
a All compounds in breath are reported as present or not present in lung cancer patients’ breath.
b Compounds in cell culture are either reported as increased or decreased arrows in quantity compared to medium controls
or shown as ‘+’ where reported without quantitation (cell lines indicated as hFB—human fibroblasts, HBEpC—human
bronchial epithelial cells).
methods such as PTR-MS and SIFT-MS have also identified
alcohols and aldehydes including isopropanol, formaldehyde
and acetaldehyde in the breath of lung cancer patients [52, 57].
The increased oxidation of alkanes to alcohols, esters and
ketones in cell culture is perhaps, not unexpected when the
environment in which cells are usually grown is considered.
Most laboratories culture cells in air with 5% carbon dioxide,
i.e. there is approximately 20% oxygen in the atmosphere
surrounding the cells. This is in contrast to the in vivo
environment.
3. Hypoxia
3.1. Hypoxia in cancer and hypoxia-inducible factor
Oxygen availability alters gene expression and metabolism
in cells, hence raising the possibility that hypoxia will
change the pattern of VOCs produced by the cancer cells.
Tumours possess extensive regions of hypoxia relative to
the corresponding normal tissue [62]. A number of adaptive
responses are initiated during cellular hypoxic stress, including
the activation of a group of transcription factors called
hypoxia-inducible factors (HIFs). Hypoxia-inducible factor-
1α (HIF-1α) has been extensively studied as an endogenous
hypoxia marker and its mechanism of accumulation under
hypoxia is well understood [63, 64]. HIF-1α regulates
an increased production of VEGF [65]. VEGF induces
neovascularization but in tumours this happens in an irregular
fashion and at a slower pace when compared to the
proliferation rate of the tumour [66, 67]. This could result
in poor blood supply and so further hypoxia.
As described in figure 1, in normoxia, HIF-1α and HIF-1β
subunits are constitutively expressed. While HIF-1α is rapidly
degraded by the proteosomal system, the amount of HIF-1β
remains constant. In hypoxia, HIF-1α escapes degradation,
binds with its partner HIF-1β, and together they bind to a
hypoxia-response element (HRE) in target genes in association
with co-activators such as CBP/P300. This triggers the
expression of multiple target genes that enable the tumour cells
to adapt to and overcome the conditions of decreased oxygen
by increasing oxygen transport, stimulating angiogenesis and
regulating glucose uptake and metabolism [68].
Recent studies show that HIF1α stabililization under
hypoxia leads to the expression of pyruvate dehydrogenase
kinase 1(PDK1) [69, 70] that phosphorylates and inactivates
pyruvate dehydrogenase (PDH), limiting the conversion of
pyruvate to Acetyl-CoA in the mitochondria (see figure 2).
Consequently, PDK1 induction decreases the tricarboxylic
acid (TCA) cycle activity, so reducing oxygen consumption.
In 1920, Otto Warburg discovered that tumours show
increased glucose consumption in converting glucose to
pyruvate and then to lactic acid despite the availability
of oxygen. Non-transformed cells also convert glucose to
pyruvate but then metabolize pyruvate through the TCA cycle
and mitochondrial oxidative phosphorylation (OXPHOS) [71].
The mitochondrial pathway requires oxygen and is much
more efficient in ATP production than anaerobic metabolism,
producing 38 versus 2 ATP molecules per molecule of glucose
as shown in figure 2 [71]. However, in an expanding tumour
mass, characterized by low levels of oxygen and a high
glucose consumption rate, anaerobic glycolysis can become
the predominant pathway of ATP generation [72]. In addition
to glycolysis, a recent study has shown that under hypoxia,
autophagy is present and is also required to support ATP
production [73].
An anticipated outcome of this hypoxic environment
would therefore be increased oxidative stress and a large
proportion of metabolites being produced as a consequence
of lipid metabolism leading to the production of alkanes and
methylated alkanes, and reduced oxidative degradation.
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Figure 1. Activation of the hypoxia-inducible factor (HIF-1α) transcription factor in normoxia and hypoxia. Figure adapted from [71].
Figure 2. Metabolic reprogramming in hypoxia: activation of HIF1- α/β activates PDK1, an inhibitor of PDH which leads to the shunting
of pyruvate away from the TCA cycle and instead it is converted to lactate. Figure adapted from [64].
Conclusion
Differences in the VOCs found in breath and in the headspace
of cancer cell lines can be attributed to many causes such
as different sampling methodology, mass spectral techniques
and statistical approaches. Here, we propose that cell culture
conditions also play a role, as it is known that hypoxia induces
autophagy and increased lipid peroxidation. This could explain
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the presence of alkanes and methylated alkanes found in breath
of the lung cancer patients. Little attention has so far been
paid to the in vitro culture conditions used to grow the cancer
cells. The hyperoxic culture conditions used to grow cells are
likely to produce more alcohols and other oxidized products
rather than the methylated alkanes and other products that are
more abundant in breath. Hence, oxygen controlled culture
conditions are the way forward for modelling the in vivo
situation. This approach should help in validating breath VOC
markers for diagnosis, clarify further how these compounds
are produced and perhaps lead to the identification of novel
VOC markers of cancer.
Acknowledgment
This work was funded by the Helen Macpherson Smith Trust,
Project No. 6858.
References
[1] Ginsberg R J, Vokes E E and Rosenzweig K 2012 Cancer:
Principles and Practice of Oncology vol 1 6th edn
ed V T De Vita, S Hellman and S A Rosenberg (Baltimore,
MD: Williams and Wilkins) p 667
[2] Mathers C D and Loncar D 2006 Projections of global
mortality and burden of disease from 2002 to 2030 PLOS
Med. 3 e442
[3] Jemal A, Center M M, DeSantis C and Ward E M 2010 Global
patterns of cancer incidence and mortality rates and trends
Cancer Epidemiol. Biomar. 19 1893–907
[4] Phillips M, Cataneo R N, Cummin A R, Gagliardi A J,
Gleeson K, Greenberg J, Maxfield R A and Rom W N 2003
Detection of lung cancer with volatile markers in the breath
Chest 123 2115–23
[5] Folkman J, Hahnfeldt P and Hlatky L 2000 Cancer: looking
outside the genome Nature Rev. Mol. Cell Bio. 1 76–79
[6] Vaupel P 2004 Tumor microenvironmental physiology and its
implications for radiation oncology Semin. Radiat. Oncol.
14 198–206
[7] Hakim M, Broza Y Y, Barash O, Peled N, Phillips M,
Amann A and Haick H 2012 Volatile organic compounds of
lung cancer and possible biochemical pathways Chem. Rev.
112 5949–66
[8] Tisch U, Billan S, Ilouze M, Phillips M, Peled N and Haick H
2012 Volatile organic compounds in exhaled breath as
biomarkers for the early detection and screening of lung
cancer CML Lung Cancer 5 107–17
[9] Miekisch W, Schubert J K and Noeldge-Schomburg G F 2004
Diagnostic potential of breath analysis—focus on volatile
organic compounds Clin. Chim. Acta 347 25
[10] Philips M 1992 Breath tests in medicine Sci. Am. 267 74–79
[11] Amann A 2012 Breath analysis for clinical diagnosis and
therapeutic monitoring Siriraj Med. J. 64 18–19
[12] Risby T H and Solga S F 2006 Current status of clinical breath
analysis Appl. Phys. B 85 421–6
[13] Mitsubayashia K, Matsunagab H, Nishiob G, Todab S
and Nakanishib Y 2005 Bioelectronic sniffers for ethanol
and acetaldehyde in breath air after drinking Biosensors
Bioelectron. 20 1573–9
[14] Ochiaia N, Takinoa M, Daishimab S and Cardinc B D 2001
Analysis of volatile sulphur compounds in breath by gas
chromatography-mass spectrometry using a three-stage
cryogenic trapping preconcentration system J. Chromatogr.
B 762 67–75
[15] Pauling L, Robinson B A, Teranishi R and Cary P 1971
Quantitative analysis of urine vapor and breath by
gas-liquid partition chromatography Proc. Natl Acad. Sci.
USA 68 2374–6
[16] Phillips M, Herrera J, Krishnan S, Zain M, Greenberg J and
Cataneo R N 1999 Variation in volatile organic compounds
in the breath of normal humans J. Chromatogr. B 729 75–88
[17] Dallinga W J, Robroeks C M H T T, Van Berkel J J B N,
Moonen E J C, Godshalk R W L, Jo¨bsis Q, Dompeling E,
Wouters E F M and Van Schooten F J 2010 Volatile organic
compounds in exhaled breath as a diagnostic tool for
asthma in children Clin. Exp. Allergy 40 68–76
[18] Van Berkel B N J J, Dallinga W J, Mo¨ller M G,
Godschalk W L R, Moonen J E, Wouters F M E and
Van Schooten J F 2010 A profile of volatile organic
compounds in breath discriminates COPD patients from
controls Respir. Med. 104 557–63
[19] Hauschild C A, Baumbach I J and Baumbach J 2012
Integrated statistical learning of metabolic ion mobility
spectrometry profiles for pulmonary disease identification
Genet. Mol. Res. 11 2733–44
[20] Baumbach J, Bunkowski A, Lange S, Oberwahrenbrock T,
Kleinbo¨lting N, Rahmann S and Baumbach J I 2007
IMS2—an integrated medical software system for early lung
cancer detection using ion mobility spectrometry data of
human breath J. Integr. Bioinform. 4 75
[21] Khalid Y T et al 2013 Breath volatile analysis from patients
diagnosed with harmful drinking, cirrhosis and hepatic
encephalopathy: a pilot study Metabolomics 9 938–48
[22] Risby T H 2008 Critical issues for breath analysis J. Breath
Res. 2 030302
[23] Miekisch W and Schubert J 2006 From highly sophisticated
analytical techniques to life-saving diagnostics: technical
developments in breath analysis Trend Anal. Chem.
25 665–73
[24] Kneepkens C M, Lepage G and Roy C C 1992 The
hydrocarbon breath test in the study of lipid peroxidation:
principles and practice Clin. Invest. Med. 15 163–86
[25] Kneepkens C M, Lepage G and Roy C C 1994 The potential of
the hydrocarbon breath test as a measure of lipid
peroxidation Free Radic. Biol. Med. 17 127–60
[26] Ray G, Batra S, Shukla N K, Deo S, Raina V, Ashok S
and Hussain S A 2000 Lipid peroxidation, free radical
production and antioxidant status in breast cancer Breast
Cancer Res. Treat. 59 163–70
[27] Loft S and Poulsen H E 1996 Cancer risk and oxidative DNA
damage in man J. Mol. Med. 74 297–312
[28] Hietanen E, Bartsch H, Bereziat J C, Camus A M, Mc
Clinton S, Eremin O, Davidson L and Boyle P 1994 Diet
and oxidative stress in breast, colon and prostate cancer
patients: a case-control study Eur. J. Clin. Nutr. 48 575–86
[29] Norberg A˚, Jones W A, Hahn G R and Gabrielsson L J 2003
Role of variability in explaining ethanol pharmacokinetics
Clin. Pharmacokinet. 42 1–31
[30] Turner C, ˇSpaneˇl P and Smith D 2006 A longitudinal study of
ethanol and acetaldehyde in the exhaled breath of healthy
volunteers using selected-ion flow-tube mass spectrometry
Rapid Commun. Mass Spectrom. 20 61–68
[31] Risby T H 2005 Trace gas analysis in exhaled human breath
for disease diagnosis CLEO: Conf. on Lasers and
Electro-Optics vol 2 pp 898–9
[32] Ledochowski M, Widner B, Murr C, Sperner-Unterweger B
and Fuchs D 2001 Fructose malabsorption is associated
with decreased plasma tryptophan Scand. J. Gastroenterol.
36 367–71
[33] Stone B G, Besse T J, Duane W C, Evans C D
and DeMaster E G 1993 Effect of regulating cholesterol
biosynthesis on breath isoprene excretion in men Lipids
28 705–8
9
J. Breath Res. 8 (2014) 027109 U Kalluri et al
[34] Phillips M, Cataneo N R, Joel G, Gunawardena R and Naidu A
2000 Effect of age on the breath methylated alkane contour,
a display of apparent new markers of oxidative stress J. Lab.
Clin. Med. 136 243–9
[35] Remmer H, Hintze T, Frank H and Mu¨h-zange M 1984
Cytochrome P-450 oxidation of alkanes originating as
scission products during lipid peroxidation Xenobiotica
14 207–19
[36] Anderson M L, Beebe E L, Fox D S, Issaq J H
and Kovatch M R 1991 Promotion of mouse lung tumors by
bioaccumulated polychlorinated aromatic hydrocarbons
Exp. Lung Res. 17 455–71
[37] Benhamou S and Bonaı¨ti-Pellie´ C 1995 Susceptibility to
bronchial cancer: an example of genetic-environmental
interaction Ann. Biol. Clin. 53 507–13
[38] Hecht S S 1997 Approaches to cancer prevention based on an
understanding of N-nitrosamine carcinogenesis Exp. Biol.
Med. 216 181–91
[39] Minro W 1998 Polymorphic CYP genes and disease
predisposition—What have the studies shown so far?
Toxicol. Lett. 167 2–3
[40] Zevin S and Benowitz N L 1999 Drug interactions with
tobacco smoking: an update Clin. Pharmacokinet.
36 425–38
[41] Buszewski B, Kesy M, Ligor T and Amann A 2007 Human
exhaled air analytics: biomarkers of diseases Biomed.
Chromatogr. 21 553–66
[42] Zolotov A Y 2005 Breath analysis J Anal Chem. 60 497
[43] Jordan A, Hansel A, Holzinger R and Lindinger W 1995
Acetonitrile and benzene in the breath of smokers and
non-smokers investigated by proton transfer reaction
mass spectrometry (PTR-MS) Int. J. Mass Spectrom.
148 L1–3
[44] Kushch I et al 2008 Compounds enhanced in a mass
spectrometric profile of smokers’ exhaled breath versus
non-smokers as determined in a pilot study using PTR-MS
J. Breath Res. 2 026002
[45] Nagrath D, Caneba C, Karedath T and Bellance N 2011
Metabolomics for mitochondrial and cancer studies
Biochim. Biophys. Acta 1807 650–63
[46] Kim Y S, Maruvada P and Milner J A 2008 Metabolomics in
biomarker discovery: future uses for cancer prevention
Future Oncol. 4 93–102
[47] Nicholson J K, Lindon J C and Holmes E 1999
‘Metabonomics’: understanding the metabolic responses of
living systems to pathophysiological stimuli via
multivariate statistical analysis of biological NMR
spectroscopic data Xenobiotica 29 1181–9
[48] Nicholson J K, Connelly J, Lindon J C and Holmes E 2002
Metabonomics: a platform for studying drug toxicity and
gene function Nature Rev. Drug Discov. 1 153–62
[49] Sponring A, Filipiak W, Mikony T, Ager C, Schubert J,
Miekisch W, Amann A and Troppmair J 2009 Release of
volatile organic compounds from the lung cancer cell line
NCI-H2087 in vitro Anticancer Res. 29 419–26
[50] Chen X, Xu F, Wang Y, Pan Y, Lu D, Wang P and Zhang W
2007 A study of the volatile organic compounds exhaled by
lung cancer cells in vitro for breath diagnosis Cancer
110 835–44
[51] Filipiak W, Sponring A, Filipiak A, Ager C, Schubert J,
Miekisch W and Tropmair J 2010 TD-GC-MS analysis of
volatile metabolites of human lung cancer and normal cells
in vitro Cancer Epidemiol. Biomarkers 19 182–95
[52] Smith D, Wang T, Sule´-Suso J, ˇSpaneˇl P and Haj A E 2003
Quantification of acetaldehyde released by lung cancer cells
in vitro using selected ion flow tube mass spectrometry
Rapid Commun. Mass Spectrom. 17 845–50
[53] Filipiak W, Sponring A, Mikoviny T, Ager C, Schubert J,
Miekisch W, Amann A and Tropmair J 2008 Release of
volatile organic compounds (VOCs) from the lung cancer
cell line CALU-1 in vitro Cancer Cell Int. 8 17
[54] Poli D, Carbognani P, Corradi M, Goldoni M, Acampa O,
Balbi B and Mutti A 2005 Exhaled volatile organic
compounds in patients with non-small cell lung cancer:
cross sectional and nested short-term follow-up study
Respir. Res. 6 71
[55] Yu J, Wang D, Wang L, Wang P, Hu Y and Ying K 2009
Detection of lung cancer with volatile organic biomarkers in
exhaled breath and lung cancer cells AIP Conf. Proc.
198 1137
[56] Yu H, Xu L and Wang P 2005 Solid phase microextraction for
analysis of alkanes and aromatic hydrocarbons in human
breath J. Chromatogr. B 826 69–74
[57] Wehinger A, Schmid A, Mechtcheriakov S, Ledochowski M,
Grabmer C, Gastl G A and Amman A 2007 Lung cancer
detection by proton transfer reaction mass-spectrometric
analysis of human breath gas Int. J. Mass Spectrom.
265 49–59
[58] Fuchs P, Loeseken C, Schubert J K and Miekisch W 2010
Breath gas aldehydes as biomarkers of lung cancer
Int. J. Cancer 126 2663–70
[59] Sponring A, Filipiak W, Ager C, Schubert J, Miekisch W,
Amann A and Troppmair J 2010 Analysis of volatile
organic compounds (VOCs) in the headspace of
NCI-H1666 lung cancer cells Cancer Biomark. 7 153–61
[60] Deng C, Zhang X and Li N 2004 Investigation of volatile
biomarkers in lung cancer blood using solid-phase
microextraction and capillary gas chromatography-mass
spectrometry J. Chromatogr. B 808 269
[61] Gordon M S, Szidon J, Krotoszynski B K, Gibbons R D
and O’Neill H J 1985 Volatile organic compounds in
exhaled air from patients with lung cancer Clin. Chem.
31 1278–82
[62] Vaupel P, Mayer A and Ho¨ckel M 2004 Tumor hypoxia and
malignant progression Method Enzymol. 381 335–54
[63] Harris A L 2002 Hypoxia—a key regulatory factor in tumour
growth Nature Rev. Cancer 2 38–47
[64] Semenza G L 2003 Targeting HIF-1 for cancer therapy Nature
Rev. Cancer 3 721–32
[65] Simiantonaki N, Jayasinghe C, Michel-Schmidt R, Peters K,
Hermanns I M and Kirkpatrick J C 2008 Hypoxia-induced
epithelial VEGF-C/VEGFR-3 upregulation in carcinoma
cell lines Int. J. Oncol. 32 585–92
[66] Jain R K 2002 Tumor angiogenesis and accessibility: role
of vascular endothelial growth factor Semin. Oncol. 29 3–9
[67] Wilson G D 2007 Hypoxia and prognosis: the oxygen tension
mounts Front. Biosci. 12 3502–18
[68] Wenger R H 2002 Cellular adaptation to hypoxia: O2-sensing
protein hydroxylases, hypoxia-inducible transcription
factors, and O2-regulated gene expression FASEB J
16 1151–62
[69] Papandreou I, Cairns R A, Fontana L, Lim A L
and Denko N C 2006 HIF-1 mediates adaptation to hypoxia
by actively downregulating mitochondrial oxygen
consumption Cell Metab. 3 187–97
[70] Kim W J, Tchernyshyov I, Semenza L G and Dang V C 2006
HIF-1-mediated expression of pyruvate dehydrogenase
kinase: a metabolic switch required for cellular adaptation
to hypoxia Cell Metab. 3 177–85
[71] Brahimi-Horn M C and Pouyssegur J 2007 Oxygen, a source
of life and stress FEBS Lett 581 3582–91
[72] Vaupel P, Kallinowski F and Okunieff P 1989 Blood flow,
oxygen and nutrient supply, and metabolic
microenvironment of human tumors: a review Cancer Res.
49 6449–65
[73] Frezza C, Zheng L, Tennant D A, Papkovsky D B,
Hedley B A, Kalna G, Watson G D and Gottlieb E 2011
Metabolic profiling of hypoxic cells revealed a catabolic
signature required for cell survival PLOS One 6 e24411
10
